Navigation Links
Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
Date:11/3/2011

THE WOODLANDS, Texas, Nov. 3, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. David Powell, senior vice president of metabolism research, will present data from clinical and preclinical studies of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), at the Cambridge Healthtech Institute's Diabetes Drug Discovery conference in Boston, Massachusetts on Friday, November 4, 2011.

In clinical studies to date, LX4211 has demonstrated a favorable safety profile and beneficial effects on multiple parameters of glycemic control and cardiovascular health.  Recent studies in healthy subjects have shown that LX4211 substantially decreases postprandial glucose levels without hypoglycemia and substantially reduces triglycerides, results that have not been reported for SGLT2-selective inhibitors.  Data from a mechanistic study in patients with type 2 diabetes demonstrated that a single dose of LX4211 significantly increased circulating levels of GLP-1 (active and total) and PYY, important regulators of glycemic and appetite control.  In addition, postprandial release of GLP-1 and PYY from the gastrointestinal (GI) tract has been observed in preclinical studies of SGLT1 knockout mice but not in SGLT2 knockout mice, indicating that inhibition of SGLT1 function may trigger the postprandial release of these important regulators of glycemic and appetite control.

For more information on this program or to download a copy of the presentation, please visit www.lexpharma.com.

About Lexicon
Lexicon is a biopharmaceutical company focused on disco
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014   LabStyle Innovations Corp . (OTCQB: ... today announced that it has closed a $4.2 ... preferred stock and warrants.  No placement agent was ... LabStyle expects to secure net proceeds of approximately ... LabStyle intends to use the net proceeds from ...
(Date:9/23/2014)... MINNETONKA, Minn. , Sept. 23, 2014   MedNet ... clinical study management systems, is pleased to announce that it ... for Clinical Data Management (SCDM) Annual Conference, to be held ... Las Vegas , Nevada. MedNet team members, in conjunction ... Partner Organizations who will also be in attendance, will ...
(Date:9/23/2014)... ORLANDO, Fla. and DUBLIN ... Inc. (OTC-BB: TNIB) ("we" or the "Company"), a ... innovative therapies for autoimmune diseases in emerging nations, ... has approved our common stock for DTC,s Deposit ... Fast Automated Securities Transfer Service ("FAST") transfer agent ...
Breaking Medicine Technology:LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5MedNet Solutions - Proud To Sponsor The SCDM 2014 Annual Conference 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 3TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 4
... Reports on 11 Patients at SAWCPRINCETON, N.J., April 29 ... (OTC Bulletin Board: DSCI), a provider of advanced ... on the Advances in Wound Care (SAWC) in Dallas, Jason ... South Florida, revealed details of a recently concluded 11-patient venous ...
... the REDUCE trial results at the American Urological Association annual ... as dutasteride (Avodart), a drug used to treat benign prostatic ... of prostate cancer in men with an increased risk of ... an additional tool in the fight against prostate cancer. ...
Cached Medicine Technology:Clinician Reports Fast Healing of Intractable Wounds Using MEDIHONEY(R) 2Clinician Reports Fast Healing of Intractable Wounds Using MEDIHONEY(R) 3Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer 2
(Date:9/23/2014)... York, NY (PRWEB) September 23, 2014 ... a moderate rate over the past five years. Growth ... health consciousness has encouraged Canadians to consume more fish ... has encouraged food retailers and food-service establishments to increase ... increasing industry revenue. Additionally, strong economic growth in much ...
(Date:9/23/2014)... 2014 Oaksterdam University has begun publishing ... its first post, the University addresses the need for ... industry. , The cannabis industry is becoming big business. ... an 18-month boost of more than $600 million in ... sales. And, the new legal recreational marijuana market in ...
(Date:9/23/2014)... "The primary purpose of the CALL LIGHT ... from Sacramento, Ca.. "Call lights are often found on the ... the IV pole out of the patient's reach. In order ... whenever they need it, I created this caddy." , She ... call device within easy reach. The accessory ensures that the ...
(Date:9/23/2014)... California, Davis, and Academia Sinica, the preeminent academic ... entered into a collaborative agreement to develop a ... cutting-edge research with opportunities to translate innovative technologies ... The agreement was signed Sept.12 in Taipei by ... Davis and President Chi-Huey Wong of Academia Sinica. ...
(Date:9/23/2014)... September 23, 2014 AttorneyOne.com, a recognized ... the latest information from the FDA on Jalapeno ... that its Private Label Jalapeno Bagels are recalled as ... Publix Jalapeno Bagels were sold in the ... , Taking into consideration the latest developments, AttorneyOne.com ...
Breaking Medicine News(10 mins):Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 3Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: ... published by the Seattle Times reporting ... incorrectly reported that CellCyte ,closes.,In CellCyte,s August 14, ... its bioreactor business segment and generally described its ...
... Dec. 29 Watson Pharmaceuticals,Inc. (NYSE: ... branded pharmaceuticals,today announced that its subsidiary, Watson Laboratories, ... Food and Drug Administration on its,Abbreviated New Drug ... USP, 0.15 mg / 0.02 mg. Desogestrel/ethinyl,estradiol ...
... Priority ReviewEAST BRUNSWICK, N.J., Dec. 29 Savient ... announced that the U.S. Food and Drug Administration ... License Application (BLA) for pegloticase, a novel biological ... also granted the Company,s BLA with a priority ...
... Cross and Blue Shield of Oklahoma announced today the ... their next policy year. This change will not in ... always been available to children with autism. Blue Cross ... interests in the benefits and coverage of certain autism-related ...
... Dec. 29 Eastern Life & Health Insurance Company (ELH), ... EIHI ), announced today that it will add vision to ... include a vision insurance plan and a vision discount program, ... "Adding vision to ELH,s product portfolio enables employers to offer ...
... 29 Life for Relief and Development (LIFE), a ... the civilian victims of the recent conflict in Gaza. ... non-governmental organizations operating in the area, LIFE has obtained ... relief items to Gaza via a specially designated humanitarian ...
Cached Medicine News:Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 2Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 3Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 4Health News:CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte 'Closes' 5Health News:Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R) 2Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 2Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 3Health News:Pegloticase BLA Filing Accepted for Priority Review by FDA 4Health News:Blue Cross and Blue Shield of Oklahoma Announces Autism Benefits 2Health News:Eastern Life & Health Introduces New Vision Product 2Health News:Eastern Life & Health Introduces New Vision Product 3
... workmanship are the hallmark of these stereozoom ... mind. The top (incident) circular 9W fluorescent ... while remaining cool to the touch. Binocular ... 10x to 44x zoom magnification or high-power ...
... system expandability: the first inverted microscope to ... infinity space. Multi-port design enables optical input/output ... variety of illumination and detector equipment. Extendable ... an optional light source and other attachments ...
... Megapixel color imaging camera system designed ... high performance, megapixel digital cameras provides ... view them on a PC via ... This "live" previewing capability is accompanied ...
... camera with direct digital output. Three-chip color ... Olympus wide array of high-quality color video ... and flexibility you need for an efficient ... high-resolution, real-time image of your specimen that ...
Medicine Products: